Back to Search
Start Over
Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML
- Source :
- Blood; November 2019, Vol. 134 Issue: 1, Number 1 Supplement 1 p5091-5091, 1p
- Publication Year :
- 2019
-
Abstract
- Introduction:On November 2018 the FDA approved the treatment of venetoclax together with hypomethylating agent (HMA) or low dose cytarabine (LDAC) for newly diagnosed AML patients who cannot tolerate intensive chemotherapy. There is limited data regarding the efficacy and safety of venetoclax in the setting of relapsed/refractory patients who received intensive chemotherapy for their disease.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 134
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs56878548
- Full Text :
- https://doi.org/10.1182/blood-2019-125662